Chlormethiazole hydrochloridePotentiates GABAA receptor function CAS# 6001-74-7 |
2D Structure
- Atglistatin
Catalog No.:BCC5104
CAS No.:1469924-27-3
- NH125
Catalog No.:BCC4001
CAS No.:278603-08-0
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 6001-74-7 | SDF | Download SDF |
PubChem ID | 19035073 | Appearance | Powder |
Formula | C6H9Cl2NS | M.Wt | 198.11 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 100 mM in water | ||
Chemical Name | 5-(2-chloroethyl)-4-methyl-1,3-thiazole;hydrochloride | ||
SMILES | CC1=C(SC=N1)CCCl.Cl | ||
Standard InChIKey | OFXYKSLKNMTBHK-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C6H8ClNS.ClH/c1-5-6(2-3-7)9-4-8-5;/h4H,2-3H2,1H3;1H | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Sedative and anticonvulsant which is neuroprotective in a number of animal models. Prevents the degeneration of serotonergic nerve terminals induced by MDMA ('Ecstasy'). |
Chlormethiazole hydrochloride Dilution Calculator
Chlormethiazole hydrochloride Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 5.0477 mL | 25.2385 mL | 50.477 mL | 100.954 mL | 126.1925 mL |
5 mM | 1.0095 mL | 5.0477 mL | 10.0954 mL | 20.1908 mL | 25.2385 mL |
10 mM | 0.5048 mL | 2.5239 mL | 5.0477 mL | 10.0954 mL | 12.6193 mL |
50 mM | 0.101 mL | 0.5048 mL | 1.0095 mL | 2.0191 mL | 2.5239 mL |
100 mM | 0.0505 mL | 0.2524 mL | 0.5048 mL | 1.0095 mL | 1.2619 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Glabrene
Catalog No.:BCN6692
CAS No.:60008-03-9
- Oblongine
Catalog No.:BCN4103
CAS No.:60008-01-7
- 11Beta-hydroxyprogesterone
Catalog No.:BCN2211
CAS No.:600-57-7
- N-Me-DL-Ala-OH.HCl
Catalog No.:BCC2618
CAS No.:600-21-5
- Adenosine cyclophosphate
Catalog No.:BCN2190
CAS No.:60-92-4
- Phloretin
Catalog No.:BCN4128
CAS No.:60-82-2
- Phlorizin
Catalog No.:BCN4126
CAS No.:60-81-1
- Antipyrine
Catalog No.:BCC8834
CAS No.:60-80-0
- Veratramine
Catalog No.:BCN2965
CAS No.:60-70-8
- Methimazole
Catalog No.:BCC3812
CAS No.:60-56-0
- Tetracycline
Catalog No.:BCC9176
CAS No.:60-54-8
- Acetyl-Strophanthidin
Catalog No.:BCC8113
CAS No.:60-38-8
- BOC-L-6-HYDROXYNORLEUCINE
Catalog No.:BCN2360
CAS No.:77611-37-1
- Alizarin 2-methyl ether
Catalog No.:BCN3480
CAS No.:6003-11-8
- GL3
Catalog No.:BCN8180
CAS No.:60037-39-0
- N-Demethylechitamine
Catalog No.:BCN4104
CAS No.:60048-88-6
- Bay 65-1942 free base
Catalog No.:BCC1408
CAS No.:600734-02-9
- Bay 65-1942 HCl salt
Catalog No.:BCC1409
CAS No.:600734-06-3
- Secologanic acid
Catalog No.:BCN8214
CAS No.:60077-46-5
- Vogeloside
Catalog No.:BCN6737
CAS No.:60077-47-6
- (1)Benzopyrano(3,4-b)furo(2,3-h)(1)benzopyran-6(12H)-one, 1,2,-dihydro-5-hydroxy-8,9-dimethoxy-2-(1-methylethenyl)-, (R)-
Catalog No.:BCN8538
CAS No.:60077-62-5
- Confluentic acid
Catalog No.:BCN4105
CAS No.:6009-12-7
- Sodium taurochenodeoxycholate
Catalog No.:BCN8152
CAS No.:6009-98-9
- Beta-D-glucopyranosiduronic acid
Catalog No.:BCN3251
CAS No.:60092-34-4
The protective action of chlormethiazole against ischaemia-induced neurodegeneration in gerbils when infused at doses having little sedative or anticonvulsant activity.[Pubmed:7599932]
Br J Pharmacol. 1995 Apr;114(8):1625-30.
1. The effect of chlormethiazole administration on delayed neuronal death in gerbil hippocampus following transient global ischaemia has been examined. Chlormethiazole was administered either intraperitoneally or by intravenous infusion with either the dose or the time of infusion varied. 2. Chlormethiazole (600 mumol kg-1, i.p.) given 60 min after ischaemia produced substantial (> 60%) neuroprotection when damage was assessed 5, 14 or 21 days later, indicating the drug does not merely delay cell death. 3. Infusion protocols were developed which would result in sustained and defined plasma concentrations. Chlormethiazole (930 mumol kg-1) was then infused intravenously for 30 min, 76.5 min or 110 min in ways resulting in sustained plasma concentrations of 200, 100 and 50 nmol ml-1 respectively. When treatment was initiated 30 min after the ischaemic episode all protocols provided effective neuroprotection. There was a dose-dependent decline in protection when plasma chlormethiazole concentrations of 50, 30 and 10 nmol ml-1 were sustained for 110 min with no protection observed at 10 nmol ml-1. 4. In contrast, when a plasma concentration of 10 nmol ml-1 was sustained by infusion for 24 h, almost total neuroprotection against the ischaemic damage was achieved. This plasma concentration produced no sedative or anticonvulsant activity. 5. These data suggest that neuroprotection depends on both dose and duration of chlormethiazole administration and that excellent neuroprotection is possible in the absence of the sedative and anticonvulsant effects of the drug.
Chlormethiazole, dizocilpine and haloperidol prevent the degeneration of serotonergic nerve terminals induced by administration of MDMA ('Ecstasy') to rats.[Pubmed:7539115]
Neuropharmacology. 1994 Dec;33(12):1589-95.
An investigation has been made into the effect of 3,4-methylenedioxymethamphetamine (MDMA or 'Ecstasy') administration on the concentration of 5-hydroxytryptamine (5-HT), uptake of [3H]5-HT and [3H]paroxetine binding in rat cerebral cortex tissue. Four days after 2 injections of MDMA (20 mg/kg i.p., 6 hr apart) the concentrations of 5-HT and its metabolite 5-HIAA were reduced by 60%. The binding of [3H]paroxetine to the presynaptic 5-HT transporter was decreased and high affinity uptake of [3H]5-HT was reduced by a similar amount, indicating neurodegeneration of 5-HT terminals. Pretreatment with chlormethiazole (100 mg/kg i.p.), 10 min before each MDMA injection prevented the decrease in both [3H]parotextine binding and uptake of [3H]5-HT. The loss in 5-HT and 5-HIAA content was also attenuated. Pretreatment with dizocilpine (1 mg/kg i.p.) or haloperidol (2 mg/kg i.p.) also prevented the MDMA-induced loss of [3H]paroxetine binding and attenuated the loss of 5-HT and 5-HIAA content. All three compounds also decreased the degree of hyperthermia that follows MDMA administration, although previous studies suggest that the long term neurodegeneration is not associated with the acute hyperthermic response. These data support the findings of others that MDMA injection produces degeneration of 5-HT nerve terminals in the cortex, confirm that chlormethiazole, dizocilpine and haloperidol attenuate MDMA-induced neurotoxic loss of 5-HT and demonstrate for the first time that these compounds prevent the neurodegeneration of 5-HT nerve terminals that follows MDMA administration.